Special:ShortPages

Shortest pages

The shortest articles by source size. A short article is not necessarily a problem, but the bottom of this list is where expansion effort pays best.

#	Article	Source bytes	Sections	Citations
1	List of GLP-1 receptor agonists	3,862	3	4
2	Retention time	4,104	3	4
3	Personal importation policy	4,121	3	4
4	Cost per milligram	4,125	3	4
5	Lixisenatide	4,195	3	4
6	Fasting insulin	4,198	3	4
7	Prior authorisation	4,216	3	4
8	Haemoglobin A1c	4,243	3	4
9	Cagrilintide	4,256	3	4
10	Triple agonist	4,269	3	4
11	ISO 9001	4,278	3	4
12	Grey market	4,279	3	4
13	Resin cleavage	4,310	3	4
14	Electrospray ionisation	4,323	3	4
15	Drug master file	4,325	3	6
16	International nonproprietary name	4,356	3	4
17	Global access disparity	4,391	3	5
18	C-peptide	4,400	3	4
19	Baseline laboratory panel	4,429	3	4
20	Regulatory status by jurisdiction	4,444	3	5
21	Timeline of incretin therapeutics	4,460	3	4
22	Liquid chromatography-mass spectrometry	4,463	3	4
23	Hypoglycaemia	4,473	3	4
24	Receptor bias	4,477	3	4
25	Sarcopenia	4,491	3	4
26	Prescribing information	4,506	3	4
27	HOMA-IR	4,511	3	4
28	Patent expiry and biosimilars	4,553	3	4
29	Active pharmaceutical ingredient	4,569	3	4
30	Batch number	4,573	3	4
31	Oral semaglutide	4,582	3	5
32	FLOW trial	4,583	3	4
33	Growth hormone secretagogue	4,613	3	4
34	Fmoc chemistry	4,618	3	4
35	Melanotan II	4,649	3	5
36	Bacteriostatic water	4,652	3	4
37	USP General Chapter 71	4,657	3	4
38	Weight regain after discontinuation	4,670	3	4
39	MOTS-c	4,670	3	4
40	Aspiration risk under anaesthesia	4,681	3	4
41	TRIUMPH trial programme	4,703	3	4
42	Number needed to treat	4,718	3	4
43	Sterile water for injection	4,738	3	5
44	Glossary of peptide terminology	4,744	3	4
45	Cold-chain freight	4,758	3	4
46	Repackaging	4,759	3	4
47	Custom peptide synthesis	4,773	3	4
48	Crude peptide	4,775	3	4
49	Sterility testing	4,776	3	4
50	Customs seizure	4,785	3	4
51	LEADER trial	4,799	3	4
52	Peptide harm reduction	4,800	3	4
53	Placebo-adjusted effect	4,805	3	4
54	Vial filling and stoppering	4,833	3	4
55	Limit of detection	4,865	3	4
56	Injection site rotation	4,872	3	4
57	Loss on drying	4,874	3	4
58	Underfilling	4,882	3	4
59	Preparative HPLC purification	4,882	3	4
60	PeptideMeter	4,925	3	4
61	Amino acid analysis	4,943	3	4
62	Insulin syringe	4,944	3	4
63	Intention-to-treat analysis	4,963	3	4
64	Dose escalation schedule	4,993	3	4
65	Contraindications of incretin therapy	4,993	3	4
66	Methionine oxidation	5,001	3	4
67	Contract development and manufacturing organisation	5,011	3	4
68	Medutest	5,018	3	4
69	SURMOUNT trial programme	5,021	3	4
70	Body composition assessment	5,029	3	4
71	VendorInvestigate	5,067	3	4
72	SURPASS trial programme	5,078	3	4
73	Enteroendocrine L cell	5,083	4	4
74	Residual solvent	5,085	3	4
75	Trifluoroacetate counterion	5,116	3	4
76	Good manufacturing practice	5,123	3	4
77	SUSTAIN trial programme	5,153	3	4
78	Chain of custody	5,157	3	4
79	SELECT trial	5,171	3	4
80	USP General Chapter 85	5,180	3	4
81	Reference standard	5,217	3	4
82	Janoshik Analytical	5,235	3	4
83	Amylin receptor agonist	5,245	3	4
84	Arcuate nucleus	5,251	3	4
85	Deamidation	5,263	3	4
86	Missed dose	5,277	3	4
87	Subcutaneous injection	5,293	3	4
88	Lot traceability	5,317	3	4
89	Bacterial endotoxin test	5,317	3	4
90	Analytical method validation	5,342	3	4
91	Solid-phase peptide synthesis	5,359	3	4
92	Test report forgery	5,391	3	4
93	Survodutide	5,445	3	4
94	Counterfeit peptide	5,488	3	4
95	Dulaglutide	5,490	3	4
96	Reverse-phase HPLC	5,499	3	4
97	Peptide aggregation	5,516	3	4
98	STEP trial programme	5,534	3	4
99	Gastric emptying	5,565	3	4
100	Satiety signalling	5,593	3	4